We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fenoldopam in Pediatric Cardiac Surgery

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00982527
First Posted: September 23, 2009
Last Update Posted: June 28, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Zaccaria Ricci, Bambino Gesù Hospital and Research Institute
  Purpose
The purpose of this study is to determine whether fenoldopam infusion during cardiopulmonary bypass in young children with congenital heart disease is able to reduce indicators of acute kidney injury (biomarkers reduction, diuresis increase) compared to a control group.

Condition Intervention Phase
Kidney Failure, Acute Drug: Placebo Drug: Fenoldopam Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Intraoperative Fenoldopam Infusion in Children Requiring Cardiopulmonary Bypass During Cardiac Surgery

Resource links provided by NLM:


Further study details as provided by Zaccaria Ricci, Bambino Gesù Hospital and Research Institute:

Primary Outcome Measures:
  • Reduction of urinary and/or serum levels of biomarker NGAL in treated group versus controls [ Time Frame: End of surgery and 12 hours postoperatively ]

Secondary Outcome Measures:
  • Reduction of urinary and/or serum levels of cystatin C, increase of diuresis and improvement of perfusion markers in treated group versus controls [ Time Frame: End of surgery and 12 hours postoperatively ]

Enrollment: 80
Study Start Date: September 2009
Study Completion Date: November 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Saline blinded infusion
Drug: Placebo
Saline continuous infusion during cardiopulmonary by pass at 1 ml/h
Other Name: saline
Drug: Fenoldopam
Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
Other Name: corlopam
Active Comparator: Fenoldopam
Drug infusion
Drug: Placebo
Saline continuous infusion during cardiopulmonary by pass at 1 ml/h
Other Name: saline
Drug: Fenoldopam
Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
Other Name: corlopam

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 365 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Children with congenital heart disease, less than one year old, undergoing surgery with the use of cardiopulmonary bypass

Exclusion Criteria:

  • Children over one year old, correction for ventricular or atrial septal defect, need for deep hypothermic circulatory arrest, preoperative renal dysfunction.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00982527


Locations
Italy
Bambino Gesù Hospital
Rome, Lazio, Italy, 00165
Sponsors and Collaborators
Bambino Gesù Hospital and Research Institute
Investigators
Principal Investigator: Zaccaria Ricci, MD Bambino Gesu Hospital
Study Director: Sergio Picardo, MD Bambino Gesù Hospital
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Zaccaria Ricci, medical doctor, Bambino Gesù Hospital and Research Institute
ClinicalTrials.gov Identifier: NCT00982527     History of Changes
Other Study ID Numbers: FSCPB-1
First Submitted: September 22, 2009
First Posted: September 23, 2009
Last Update Posted: June 28, 2012
Last Verified: June 2012

Keywords provided by Zaccaria Ricci, Bambino Gesù Hospital and Research Institute:
cardiopulmonary bypass
pediatric cardiac surgery
acute renal failure
renal biomarkers
fenoldopam
Focus on optimization of perfusion during pediatric CPB

Additional relevant MeSH terms:
Renal Insufficiency
Acute Kidney Injury
Kidney Diseases
Urologic Diseases
Fenoldopam
Antihypertensive Agents
Vasodilator Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs